rituximab

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.

Laprituximab emtansine (IMGN-289), an immunotoxin targeting HER1, is an EGFR antibody-drug conjugate (ADC) composed of J2898A antibody, DM1 (anti-microtubule agent), and the SMCC thioether linker, utilized in cancer research [1] [2] [3].

Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell killing by T-cells and natural killer cells, and enhancing the cytotoxicity of Rituximab.Urelumab has been used in the study of solid tumor-related diseases such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Urelumab can be used to study diseases associated with solid tumors such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.

BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).